Rein Therapeutics (NASDAQ: RNTX) presented Tuesday September 8, 2026 (poster PA6217, 12:30-2:00 p.m. CEST) at the European Respiratory Society Congress in Barcelona the Phase 1b randomized double-blind placebo-controlled dose-escalation study of inhaled LTI-03 in patients with idiopathic pulmonary fibrosis. LTI-03 is a first-in-class synthetic seven-amino-acid peptide derived from the caveolin-1 scaffolding domain (CSD), designed with a dual mechanism targeting alveolar epithelial cell survival and inhibition of profibrotic signaling. The trial randomized 24 IPF participants 3:1 to LTI-03 5 mg/day (N=9), LTI-03 10 mg/day (N=9), or placebo (N=6) for 14 days. LTI-03 was well-tolerated with no treatment-related discontinuations, no severe TEAEs, and no spirometry-based airway obstruction; both doses significantly reduced interleukin-11 (p=0.0406 at 5 mg/day; p=0.044 at 10 mg/day) and thymic stromal lymphopoietin. The results were published the same day in Nature Communications (Philip Molyneaux MD, Imperial College London, presenting). LTI-03 has FDA Orphan Drug and Fast Track designations (Fast Track granted August 2026); the Phase 2 RENEW trial is enrolling across five countries with interim data anticipated H2 2026.
GSK (NYSE: GSK) announced Tuesday September 1, 2026 that its mRNA seasonal influenza vaccine candidate will advance to Phase 3 development in September 2026 following positive Phase 2 immunogenicity data presented at the OPTIONS XIII Conference for the Control of Influenza. The vaccine candidate demonstrated higher immune responses against all influenza strains tested compared to licensed standard-dose and high-dose inactivated flu vaccines in both younger and older adults, and was generally well tolerated. Differentiation: GSK's vaccine is the first mRNA flu candidate to advance to Phase 3 designed to target both hemagglutinin (HA) and neuraminidase (NA), the two primary influenza surface antigens; licensed flu vaccines primarily target HA. Growing evidence suggests dual HA-plus-NA targeting could improve protection, illness severity, and transmission reduction. The FDA granted Fast Track designation in July 2026. The advancement sets up direct Phase 3 competition with Moderna's mNEXSPIKE (approved May 2025) and Pfizer's mRNA flu program, extending the mRNA respiratory-vaccine class beyond COVID-19.
SOTIO Biotech (a portfolio company of PPF Group) announced Tuesday July 14, 2026 that the US Food and Drug Administration (FDA) granted Fast Track Designation to SOT109, its investigational potentially best-in-class antibody-drug conjugate (ADC), for the treatment of patients with advanced unresectable or metastatic colorectal cancer (CRC) who have exhausted standard treatment options. SOT109 targets cadherin 17 (CDH17), a cell-surface antigen expressed in more than 90% of CRC cases and broadly across gastrointestinal malignancies, supporting the case for broad clinical utility and a favorable therapeutic index. SOTIO expects to initiate a Phase 1/2 trial of SOT109 in patients with advanced unresectable or metastatic CRC in Q3 2026. Fast Track Designation allows more frequent FDA-sponsor interactions and eligibility for accelerated approval and priority review if criteria are met. The SOT109 program extends the broader payload-and-linker-chemistry investment thesis anchored by Novartis's July 6 Myricx Bio $1.5 billion NMTi acquisition and Lonza's July 2 Nona Biosciences TfR1 BBB-delivery deal.